Sentence examples for microarrays were developed from inspiring English sources

Therefore, a total number of 6 microarrays were developed (3 control pools, named C1, C2, C3, and 3 estradiol-treated pools named E1, E2 and E3).

Furthermore, Brassica microarrays were developed to confirm Brassica-specific expressed genes [ 19].

Previously, microarrays were developed from PCR amplicons (cDNA microarrays) primarily in pines and spruces (reviewed in [ 12]).

The custom microarrays were developed for the A. formosa holobiont prior to the removal of sequences with blastx matches to prokaryotes, therefore 5.8% of microarray probes represent non-quality assured sequence matches.

Genome-based DNA microarrays were developed to genotype a number of human pathogens, including Escherichia coli [ 43], for which Geue and colleagues were able to discriminate 446 Shiga-toxin-producing E. coli [ 44].

Human oligonucleotide microarrays were developed using 29550 oligonucleotides derived from 30 K MWG Human Oligo Set with 50 bp in length (provided by Prof. Reinhard Kofler, Tyrolian Cancer Research Institute), and dissolved in spotting buffer consisting of 3× SSC, 1.5 M Betaine.

In addition, a set of unique 70 base pair oligomers that can be used for DNA microarrays was developed.

A rapid molecular technique to detect resistance to second-line drugs in MTB using hybridisation analysis on microarrays was developed in this study.

The technology behind microarrays was developed over the past several years once it became apparent that new, more powerful analytical approaches were needed to utilize the flood of genomic data and resources being acquired through the various genome projects.

Next, a map of the complete striatal transcriptome, based on the level of correlation between profiles of all transcripts measured using microarrays, was developed in order to depict drug-induced alterations in expression.

To facilitate genetic cascade screening for familial hypercholesterolemia (FH) in Europe, two versions (7 and 9) of a DNA microarray were developed to detect the most frequent point mutations in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) genes.